The Company is currently engaged in the scale out and deployment of the Fionet solution which is very hectic given the demand for testing globally. Included in these activities has been getting the organization properly capitalized to fulfill demand and scale out commercial infrastructure & HR. The Company has successfully raised over $8.5M and seen over $3M exercised by option and warrant conversion.
At the same time the Company’s Glow Lifetech sub has closed its financing and is set to go public. The company has also embarked on commercial operations related to the artemic potential covid treatment candidate. This asset has been cultivated by the company over the last 18 months and has a considerable stake in the venture.
The Company will be reporting on material current and ongoing commercial deployments shortly, as well as update on ongoing development.
W. Clark Kent, President
Relay Medical Corp.